Not yet recruiting NCT05327673
Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: questionnaire.
- Who it may be relevant to
- Registry conditions: Allogeneic Hematopoietic Stem Cell Transplantation. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland France on the alloSCT on both patients, their caregivers and the healthcare system. It is organised in 3 working packages (WP).
Interventions
- Other questionnaire
* quality of life score: FACT-BMT * decisional conflict scale * Discreet Choice Experiment questionnaire
Primary outcome measures
- Quality of life Functional Assessment of Cancer Therapy - Bone Marrow Transplantation questionnaire. (FACT-BMT questionnaire) [Time frame: 24 months]
Secondary outcome measures (5)
- satisfaction with decision questionnaire [Time frame: 24 months]
- decision regret scale [Time frame: 24 months]
- fear of recurrence questionnaire [Time frame: 24 months]
- preferences of patients questionnaire [Time frame: 24 months]
- cost of treatment [Time frame: 24 months]
Eligibility criteria
Inclusion criteria
- patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome
- candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ;
- Residing in Reunion Island
- Age >18 year old;
- who accept or not allogeneic hematopoietic
- Able to complete a questionnaire
Exclusion criteria
- Opposition to participation and collection of their data
- Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU de la Réunion — Saint-Pierre
Identifiers
NCT: NCT05327673 · 2020/CHU/21